Clinical studies have linked expression of the EGFR ligand AREG to poor prognosis of patients suffering from carcinomas such as pancreatic, breast, or colorectal cancer (Willmarth & Ethier, 2008; Yamada et al, 2008; Wang et al, 2016). This evidence concerns the gene EGFR and colorectal cancer.